Company / Operating Cash Flow
Astria Therapeutics, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$81.2M
FY2024
5-year range
-$81.2M / -$30.2M
FY2020-FY2024
Trend
-18.7%
vs FY2023
Sector context
#113 of 216
Health Care
What the data says
At -$81M, Astria Therapeutics, Inc.'s operating cash flow ranks #113 of 216 in the Health Care sector. Operating Cash Flow has declined for 3 consecutive years, from -$30M in FY2021 to -$81M in FY2024.
Based on SEC 10-K filings.
-$81M in FY2024.
Declined from -$44M to -$81M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#113 of 216 in Health CareTop 52% of 216This company -$81.2M Sector average $658.7M
▼
-112.3% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2024, operating cash flow decreased 18.7% year-over-year.
- Ranks #113 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$81.2M | -18.7% |
| FY2023 | -$68.4M | -57.2% |
| FY2022 | -$43.5M | -44.4% |
| FY2021 | -$30.2M | +7.2% |
| FY2020 | -$32.5M | -22.3% |
| FY2019 | -$26.6M | -13.2% |
| FY2018 | -$23.5M | +12.6% |
| FY2017 | -$26.8M | +18.3% |
| FY2016 | -$32.9M | -10.3% |
| FY2015 | -$29.8M | -46.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026